• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Targeting the PI3K/AKT/mTOR pathway in prostate cancer development and progression

Bioengineer by Bioengineer
June 10, 2016
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

The research article – Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy, by Dr Claudio Festuccia (University of L’Aquila, Italy) and published in Clinical Cancer Drugs, volume 3, issue 1 – discusses experimental and clinical data on the pharmacological inhibition of the Akt/mTOR pathways. These pathways play a key role in the modulation of cellular proliferation, tumor growth and survival through phosphorylation of different downstream molecules. Prostate tumor growth and progression is negatively regulated by Phosphatase and tensin homolog (PTEN) which is genetically and/or functionally silenced in this neoplasia. The aim of the presentation was to analyze the synthesis and functional characterization of different compounds inhibiting phospatidylinositol-4,5-bisphosphate-3-kinase (PI3K), Akt and mTOR activities as well as the feasibility of these inhibitors functioning alone or in combination with standard therapies in aggressive castration resistant prostate cancers (CRPC), a disease stage characterized from high percentage of patients with bone metastases. Conventional treatment for this disease stage requires, indeed, a multidisciplinary approach (medical therapy, surgery, and radiation), but is primarily palliative. Pharmacological resistance is commonly observed. Activation of PI3K/Akt/mTOR pathways plays a significant role in therapy. The blockade of this pathway may be necessary to increase standard therapies. “Several preclinical data support the rationale to advance the use of pharmacological inhibitors of PI3k/Akt/mTOR into clinical trials in CRPC as performed for several other solid tumors” remarked Dr. Festuccia.

###

Author(s): Festuccia Claudio.

Affiliation: Department of Clinical and Applied Sciences and Biotechnologies, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, Italy

This article is open access and can be downloaded from Bentham Science Publishers’ webpage here: http://benthamscience.com/journals/clinical-cancer-drugs/volume/3/issue/1/page/36/

Media Contact

Faizan ul Haq
[email protected]
@BenthamScienceP

http://benthamscience.com/

The post Targeting the PI3K/AKT/mTOR pathway in prostate cancer development and progression appeared first on Scienmag.

Share102Tweet8Share2ShareShareShare2

Related Posts

blank

Whole Brain Radiotherapy vs. Integrated Boost Efficiency

August 3, 2025
blank

Intrapleural Anti-VEGF Boosts Nab-Paclitaxel Efficacy

August 2, 2025

Saliva Exosome Proteins and Lipids Diagnose Esophageal Cancer

August 2, 2025

Azelaic Acid Blocks Leukemia Cell Skin Trafficking

August 2, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    45 shares
    Share 18 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Deep Learning Predicts Myopia Severity Accurately

Whole Brain Radiotherapy vs. Integrated Boost Efficiency

Metabolic Traits Conserved and Diverged in Tumors, Xenografts

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.